Sangbin Han, Gaabsoo Kim, Suk‐Koo Lee, Choon Hyuck David Kwon, Misook Gwak, Sanghoon Lee, Sangyun Ha, Cheol‐Keun Park, Justin Sangwook Ko, Jaewon Joh – 31 March 2014 – A safe use of intermittent hepatic inflow occlusion (IHIO) has been reported for living donor hepatectomy. However, it remains unclear whether the maneuver is safe in steatotic donors. In addition, the respective importance of macrosteatosis (MaS) and microsteatosis (MiS) is an important issue. Thus, we compared MiS and MaS with respect to the tolerance of hepatic ischemia/reperfusion (IR) injury induced by IHIO.

Marcus Robertson, Avik Majumdar, Kent Garrett, Greg Rumler, Paul Gow, Adam Testro – 31 March 2014

Marcus Robertson, Avik Majumdar, Kent Garrett, Greg Rumler, Paul Gow, Adam Testro – 31 March 2014

Raymond Ng, Heng Wu, Hong Xiao, Xin Chen, Holger Willenbring, Clifford J. Steer, Guisheng Song – 28 March 2014 – The incidence of nonalcoholic fatty liver disease (NAFLD) and hyperlipidemia, with their associated risks of endstage liver and cardiovascular diseases, is increasing rapidly due to the prevalence of obesity. Although the mechanisms of NAFLD have been studied extensively, the underlying pathogenesis and the role of microRNAs in this process remain relatively unclear.

Alan J. Wigg, Mohamed A. Chinnaratha, Rachel Wundke, Michael L. Volk – 28 March 2014

Liesl M. Hagan, Mark S. Sulkowski, Raymond F. Schinazi – 28 March 2014 – Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)‐ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks.

Liesl M. Hagan, Mark S. Sulkowski, Raymond F. Schinazi – 28 March 2014 – Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)‐ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks.

Alan J. Wigg, Mohamed A. Chinnaratha, Rachel Wundke, Michael L. Volk – 28 March 2014

Monika Sarkar, Norah A. Terrault – 26 March 2014

Wei‐Heng Xu, Hong‐Gang Hu, Yuan Tian, Shao‐Zhan Wang, Jie Li, Jian‐Zhong Li, Xing Deng, Hui Qian, Lei Qiu, Zhen‐Lin Hu, Qiu‐Ye Wu, Yi‐Feng Chai, Cheng Guo, Wei‐Fen Xie, Jun‐Ping Zhang – 26 March 2014 – Liver fibrosis and its endstage, cirrhosis, represent a major public health problem worldwide. Activation of hepatic stellate cells (HSCs) is a central event in hepatic fibrosis. However, the proteins that control HSC activation are incompletely understood.